Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
nn9CMEz2mh1zBNtC